Brenda Reynolds

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985.

PowderMed Ltd. develops immunotherapeutic products. It focuses on the clinical development and manufacture of therapeutic and prophylactic DNA-based vaccines for viral diseases and cancer. The company has 4 clinical and 3 pre-clinical stage projects. The company was founded February 25, 2004 by Dr. Clive Dix & Dr. Beadle and is headquartered at Oxford, The United Kingdom.

Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom.

DC Biosciences Ltd. provides bioreagents and life science services. The firm’s products include cell extracts, fresh primary mammalian cells, recombinant proteins, steroid beads, fluorescent cell markers, and SILAC reagents. Its services include custom antibody service, custom antibody service, DNA cloning services, gene synthesis service, and protein expression, gene to stable cell line, mass spectrometry, quantitative proteomics, and peptide synthesis. The company was founded by Angus Lamond and Paul Ajuh in June 2006 and is headquartered in Dundee, the United Kingdom.

iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.